Cephalon To Buy Swiss Drugmaker Mepha For $590M

By Eric Hornbeck

Law360, New York (February 01, 2010, 1:58 PM ET) -- Cephalon Inc. has agreed to pay about $590 million (622.5 million Swiss francs) for the privately held Swiss pharmaceutical company Mepha AG, the companies announced Monday.

The companies anticipate that the deal will close within the next 12 weeks, pending certain closing conditions and clearing antitrust hurdles, they announced in a joint statement.

The deal will double the size of Pennsylvania-based Cephalon's international business and diversify its product lineup. The combined company will have a presence in 100 countries, and 30 percent of its sales will...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles